Comparison of Acyclovir and Vidarabine in Immunocomtxomised Children with Varicella‐Zoster virus Infection

Taiji Kunitomi, Ayumi Akazai, Masanori Ikeda, Megumi Oda, Nobuyuki Kodani

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Intravenous acyclovir and vidarabine were compared in the treatment of varicella‐zoster virus (VZV) infection in 25 immunocompromised children ‐ 13 with acute lymphocytic leukemia, three with other types of cancer, two with immunodeficiency and in seven undergoing prednisolone treatment. Thirteen had varicella and 12 had herpes zoster. Acyclovir was given intravenously to five patients with varicella and to four with herpes zoster at a dose of 5–10 mg/kg every eight hours. Vidarabine was given intravenously to eight patients with varicella and to eight with herpes zoster at a dose of 10 mg/kg/day. In varicella, vidarabine significantly shortened the time from the start of treatment to cessation of new lesion formation compared with acyclovir. However, there was no significant difference in time to complete crusting between the two treatments. In herpes zoster, acyclovir significantly shortened the time from the onset of the skin lesions to complete crusting. A slight raise of GOT in two cases was reported. While acyclovir and vidarabine were equally effective for VZV infection, in herpes zoster acyclovir was more effective.

Original languageEnglish
Pages (from-to)702-705
Number of pages4
JournalPediatrics International
Volume31
Issue number6
DOIs
Publication statusPublished - 1989

Fingerprint

Vidarabine
Acyclovir
Virus Diseases
Herpes Zoster
Chickenpox
Withholding Treatment
Prednisolone
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutics
Skin

Keywords

  • Acyclovir
  • Cancer
  • lmmunocompromised children
  • Varicella‐zoster
  • Vidarabine

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Comparison of Acyclovir and Vidarabine in Immunocomtxomised Children with Varicella‐Zoster virus Infection. / Kunitomi, Taiji; Akazai, Ayumi; Ikeda, Masanori; Oda, Megumi; Kodani, Nobuyuki.

In: Pediatrics International, Vol. 31, No. 6, 1989, p. 702-705.

Research output: Contribution to journalArticle

Kunitomi, Taiji ; Akazai, Ayumi ; Ikeda, Masanori ; Oda, Megumi ; Kodani, Nobuyuki. / Comparison of Acyclovir and Vidarabine in Immunocomtxomised Children with Varicella‐Zoster virus Infection. In: Pediatrics International. 1989 ; Vol. 31, No. 6. pp. 702-705.
@article{c31d948c63e74734bee3c2fb5120d25d,
title = "Comparison of Acyclovir and Vidarabine in Immunocomtxomised Children with Varicella‐Zoster virus Infection",
abstract = "Intravenous acyclovir and vidarabine were compared in the treatment of varicella‐zoster virus (VZV) infection in 25 immunocompromised children ‐ 13 with acute lymphocytic leukemia, three with other types of cancer, two with immunodeficiency and in seven undergoing prednisolone treatment. Thirteen had varicella and 12 had herpes zoster. Acyclovir was given intravenously to five patients with varicella and to four with herpes zoster at a dose of 5–10 mg/kg every eight hours. Vidarabine was given intravenously to eight patients with varicella and to eight with herpes zoster at a dose of 10 mg/kg/day. In varicella, vidarabine significantly shortened the time from the start of treatment to cessation of new lesion formation compared with acyclovir. However, there was no significant difference in time to complete crusting between the two treatments. In herpes zoster, acyclovir significantly shortened the time from the onset of the skin lesions to complete crusting. A slight raise of GOT in two cases was reported. While acyclovir and vidarabine were equally effective for VZV infection, in herpes zoster acyclovir was more effective.",
keywords = "Acyclovir, Cancer, lmmunocompromised children, Varicella‐zoster, Vidarabine",
author = "Taiji Kunitomi and Ayumi Akazai and Masanori Ikeda and Megumi Oda and Nobuyuki Kodani",
year = "1989",
doi = "10.1111/j.1442-200X.1989.tb01383.x",
language = "English",
volume = "31",
pages = "702--705",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Comparison of Acyclovir and Vidarabine in Immunocomtxomised Children with Varicella‐Zoster virus Infection

AU - Kunitomi, Taiji

AU - Akazai, Ayumi

AU - Ikeda, Masanori

AU - Oda, Megumi

AU - Kodani, Nobuyuki

PY - 1989

Y1 - 1989

N2 - Intravenous acyclovir and vidarabine were compared in the treatment of varicella‐zoster virus (VZV) infection in 25 immunocompromised children ‐ 13 with acute lymphocytic leukemia, three with other types of cancer, two with immunodeficiency and in seven undergoing prednisolone treatment. Thirteen had varicella and 12 had herpes zoster. Acyclovir was given intravenously to five patients with varicella and to four with herpes zoster at a dose of 5–10 mg/kg every eight hours. Vidarabine was given intravenously to eight patients with varicella and to eight with herpes zoster at a dose of 10 mg/kg/day. In varicella, vidarabine significantly shortened the time from the start of treatment to cessation of new lesion formation compared with acyclovir. However, there was no significant difference in time to complete crusting between the two treatments. In herpes zoster, acyclovir significantly shortened the time from the onset of the skin lesions to complete crusting. A slight raise of GOT in two cases was reported. While acyclovir and vidarabine were equally effective for VZV infection, in herpes zoster acyclovir was more effective.

AB - Intravenous acyclovir and vidarabine were compared in the treatment of varicella‐zoster virus (VZV) infection in 25 immunocompromised children ‐ 13 with acute lymphocytic leukemia, three with other types of cancer, two with immunodeficiency and in seven undergoing prednisolone treatment. Thirteen had varicella and 12 had herpes zoster. Acyclovir was given intravenously to five patients with varicella and to four with herpes zoster at a dose of 5–10 mg/kg every eight hours. Vidarabine was given intravenously to eight patients with varicella and to eight with herpes zoster at a dose of 10 mg/kg/day. In varicella, vidarabine significantly shortened the time from the start of treatment to cessation of new lesion formation compared with acyclovir. However, there was no significant difference in time to complete crusting between the two treatments. In herpes zoster, acyclovir significantly shortened the time from the onset of the skin lesions to complete crusting. A slight raise of GOT in two cases was reported. While acyclovir and vidarabine were equally effective for VZV infection, in herpes zoster acyclovir was more effective.

KW - Acyclovir

KW - Cancer

KW - lmmunocompromised children

KW - Varicella‐zoster

KW - Vidarabine

UR - http://www.scopus.com/inward/record.url?scp=84995097942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995097942&partnerID=8YFLogxK

U2 - 10.1111/j.1442-200X.1989.tb01383.x

DO - 10.1111/j.1442-200X.1989.tb01383.x

M3 - Article

C2 - 2516397

AN - SCOPUS:84995097942

VL - 31

SP - 702

EP - 705

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 6

ER -